Some useful links to MPN information resources, guidelines and detailed research articles are provided below.
2023 International MPN patient conference videos (discusses 2023 treatment updates for ET, PV and MF)
Presentations and videos for MPN patients from the world’s leading MPN experts – courtesy MPN Education Foundation
ASH 2022 meeting
Brief video summary of ground breaking findings – Dr Ruben Mesa, courtesy of MPN Advocacy and Education International
2022 MPN Horizons International Conference
Video presentations
COVID-19 – please refer to our COVID-19 specific page.
ALL MPNs
- US National Comprehensive Cancer Network (NCCN) Guidelines for Patients: Myeloproliferative Neoplasms – 2022
- Myeloproliferative neoplasms: Classifications and an approach to diagnosis, Australian Journal of General Practice, 2021
- WHO Classification and Diagnostic Criteria for Myeloproliferative Neoplasms: document summary and in-depth discussion
- The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations , 2017
- Splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies, Critical review, AJH 2023
- Splanchnic vein thrombosis – a national retrospective cohort study of MPN-SVT, courtesy of MPN Hub, 2022
- Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
- Clinical features associated with thrombotic events in children with myeloproliferative neoplasms 2022
- Characterization of myeloproliferative neoplasms in the paediatric and young adult population, BJH 2023
- Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms , 2020
- Basis of Hematocrit Treatment Guideline for PV: Cardiovascular Events and the Intensity of Treatment in Polycythaemia Vera, ‘NEJM’, 2013
Women and MPNs
- Best practice recommendations for the management of MPN in pregnant patients, courtesy of MPN Hub, 2021
(Please note that these are not Australian guidelines and local Australian practices may differ.) - Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms—a nationwide population-based study of 342 pregnancies in Sweden, 2022
Essential thrombocythaemia (ET) specific information
- Site specific venous thrombosis in ET: impact on subsequent vascular events and survival, ‘Journal of thrombosis and haemostasis’, 2022
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk stratification and management, USA
- Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet, 2021
- Updates in the management of polycythemia vera and essential thrombocythemia – USA, August 2019
- Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Polycythaemia Vera (PV) specific information
- Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b, Leukemia 2022
- Real world evaluation of association between elevated blood counts and thrombotic events: analysis of data from REVEAL study, 2022 (courtesy of MPN Hub)
- Appropriate management of polycythaemia vera with cytoreductive drug therapy – European LeukemiaNet recommendations, 2021
- A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline 2019
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management, USA
- Updates in the management of polycythemia vera and essential thrombocythemia -USA, August 2019
- A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis – A British Society for Haematology Guideline 2018
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Myelofibrosis (MF) specific information
- Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology (myelofibrosis focus)
- Primary myelofibrosis: 2021 update on diagnosis, risk stratification and management
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia, Journal of Hematology and Oncology, 2022
- A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study, Therapeutic Advances in Hematology, 2022
- Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis, Blood Cancer Journal, 2021
- Prefibrotic Myelofibrosis treatment information 2018
- Myelofibrosis Stem Cell Transplant (SCT) Timing Tool
- Survival following allogeneic transplant in patients with myelofibrosis
- Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, AJH, 2023
- Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis, AJH, 2022
Treatments
- FACT SHEETS are provided on all the main treatments available for Australian MPN patients. These are available in several languages.
- Articles on MPN treatment – this includes a conversation with an MPN specialist about how interferons work in MPN patients, comparisons of interferon and hydroxyurea and exciting new developments for myelofibrosis treatments.
Blood tests
Genetics Information
- Life histories of myeloproliferative neoplasms inferred from phylogenies, Nature 2022
- Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population, Blood 2019
- Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
- Genetics Home Reference – Your Guide to Understanding Genetic Conditions
- ET https://ghr.nlm.nih.gov/condition/essential-thrombocythemia
- PV https://ghr.nlm.nih.gov/condition/polycythemia-vera#resources
- MF https://ghr.nlm.nih.gov/condition/primary-myelofibrosis
Links to information on various genetic mutations
- JAK2 https://ghr.nlm.nih.gov/gene/JAK2
- CALR https://ghr.nlm.nih.gov/gene/CALR
- MPL https://ghr.nlm.nih.gov/gene/MPL#resources
- TET2 https://ghr.nlm.nih.gov/gene/TET2#conditions
Pediatric and Young Adult MPNs
- Weill Cornell Medicine Pediatric Myeloproliferative Neoplasm Program
- Characterization of myeloproliferative neoplasms in the paediatric and young adult population, BJH 2023
- Clinical features associated with thrombotic events in children with myeloproliferative neoplasms 2022
- Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs, Blood Advances, 2022
